demonstrate

Three-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPHThree-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

Three-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

SOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the results of long-term data demonstrating…

1 week ago
Industry’s First-to-Market Supermicro NVIDIA HGX B200 Systems Demonstrate AI Performance Leadership on MLPerf Inference v5.0 ResultsIndustry’s First-to-Market Supermicro NVIDIA HGX B200 Systems Demonstrate AI Performance Leadership on MLPerf Inference v5.0 Results

Industry’s First-to-Market Supermicro NVIDIA HGX B200 Systems Demonstrate AI Performance Leadership on MLPerf Inference v5.0 Results

Latest Benchmarks Show Supermicro Systems with the NVIDIA B200 Outperformed the Previous Generation of Systems with 3X the Token Generation…

1 month ago
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisLate-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…

2 months ago
ST Engineering iDirect to Demonstrate Intuition’s Next-Gen Capabilities at Satellite 2025ST Engineering iDirect to Demonstrate Intuition’s Next-Gen Capabilities at Satellite 2025

ST Engineering iDirect to Demonstrate Intuition’s Next-Gen Capabilities at Satellite 2025

Witness the power of advanced automation, multi-orbit connectivity and cloud-driven scalability in action   HERNDON, Va., March 5, 2025 /PRNewswire/…

2 months ago
Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing IntervalsThree-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…

3 months ago